KAB90001
Colorimetric
Plasma, Serum
Quantitative
156.25 - 10,000 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
5G1.1,h5G1.1HuG2/G4,CAS: 219685-50-4
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies., PMID:40515823
Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance., PMID:40515788
DAGLA autoantibody experience at Mayo Clinic., PMID:40512252
Complement inhibition rapidly blocks lesion extension and facilitates remyelination in neuromyelitis optica., PMID:40506785
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618
Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how., PMID:40505554
[A case of paroxysmal nocturnal hemoglobinuria treated with eculizumab in unintended pregnancy]., PMID:40484825
[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823
An updated, comprehensive meta-analysis of the treatment of anti-NMDAR encephalitis: Analysis, equipoise, and the urgent need for evidence over anecdote., PMID:40472799
Complement inhibitor therapy as a steroid-sparing strategy in generalized myasthenia gravis., PMID:40453104
From checkboxes to emojis: a novel approach to patient-reported outcomes in multiple sclerosis., PMID:40447786
Oral iptacopan monotherapy in paroxysmal nocturnal haemoglobinuria: final 48-week results from the open-label, randomised, phase 3 APPLY-PNH trial in anti-C5-treated patients and the open-label, single-arm, phase 3 APPOINT-PNH trial in patients previously untreated with complement inhibitors., PMID:40447351
Case Report: Hematopoietic Stem Cell Transplantation to Treat Severe Acquired Aplastic Anemia in a Pediatric Kidney Transplant Recipient., PMID:40445946
Advances in Research on the Release of von Willebrand Factor from Endothelial Cells through the Membrane Attack Complex C5b-9 in Sepsis., PMID:40438181
Atypical Haemolytic Uraemic Syndrome., PMID:40436118
Hypertensive Emergency and Atypical Hemolytic Uremic Syndrome Associated with Cocaine Use: A Diagnostic and Therapeutic Challenge., PMID:40422585
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242
Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature., PMID:40414204
Validation for soluble C5b-9 detection and comparative analysis of three quantification methods., PMID:40412754
Translating biomarker insights into practice: a path forward in TA-TMA management., PMID:40406401
Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case., PMID:40398846
Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis., PMID:40392453
Atypical hemolytic uremic syndrome: a rare complication of postendoscopic retrograde cholangiopancreatography pancreatitis., PMID:40386314
Kidney transplant in patients with C3 glomerulopathy., PMID:40385590
PLASMIC score to aid diagnosis of aHUS: an analysis of C5 inhibitor clinical trials and the PINC AI™ healthcare database., PMID:40375186
Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials., PMID:40356951
Advancements in Complement Inhibition for PNH and Primary Complement Mediated Thrombotic Microangiopathy., PMID:40354320
Comparative efficacy and acceptability of novel biologics in the treatment of myasthenia gravis: systematic review and network meta-analysis of randomized trials., PMID:40346603
Eculizumab in severe pediatric STEC-HUS and its impact on neurological prognosis-a systematic review and meta-analysis., PMID:40341411
Drug-Induced Thrombotic Microangiopathy Arising During the Treatment of Anal Carcinoma After the Use of Mitomycin C., PMID:40330382
Rapid response of eculizumab: a rescue therapy for ventilator-dependent refractory myasthenic crisis., PMID:40327031
Interferon Causes Endothelial Injury in Humans., PMID:40326264
Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120
Utility of spinal cord axial-T2 sequence in a population-based cohort of multiple sclerosis., PMID:40301133
Complement dysregulation at lymphatics., PMID:40300720
Correction: A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients., PMID:40299078
Eculizumab as fast-acting rescue therapy for pembrolizumab-induced impending crisis state of myasthenia gravis: a case report., PMID:40297820
Eculizumab as Treatment in Refractory Impeding and Myasthenic Crisis: A Case Series., PMID:40295418
Assessing fall risk in multiple sclerosis using patient-reported outcomes and wearable gait metrics., PMID:40292035
Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria., PMID:40285403
Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice., PMID:40283639
Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report., PMID:40276419
Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment., PMID:40273330
Neuromyelitis optica spectrum disorder in Latin America: a global data share initiative., PMID:40267692
Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report., PMID:40264782
Late Relapse After Autologous Hematopoietic Stem Cell Transplantation in AQP4-IgG-Positive NMOSD., PMID:40257801
The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment., PMID:40257298
Eculizumab is efficacious and safe in pediatric patients with various forms of hemolytic uremic syndrome: a retrospective clinical experience of a tertiary center., PMID:40255570
Paroxysmal nocturnal haemoglobinuria in pregnancy-a systematic review with meta analysis., PMID:40244439
Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension., PMID:40241307
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
